Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05704933 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT05704933: Completed Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT05704933 is a Early Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 1 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05704933, a Early Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug.
Primary Outcome
Feasibility is defined as being able to recruit 8 patients per treatment arm (16 total) within 30 months.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Nivolumab + Relatlimab
- PROCEDURE Standard of Care Craniotomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2024-08-20 |
| Phase | Early Phase 1 |
What the finished NCT05704933 record still lists
NCT05704933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT05704933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05704933 about?
NCT05704933 is a clinical study titled "Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases". The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug.
What is the current status of trial NCT05704933?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2023-06-06. Estimated completion is 2024-08-20.
What interventions are being tested in trial NCT05704933?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Nivolumab + Relatlimab (DRUG), Standard of Care Craniotomy (PROCEDURE).
Who is sponsoring clinical trial NCT05704933?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05704933's enrollment target sits among peer trials
1 1986th of 2000 the lowest of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI